论文信息 - Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough - 字舞流文

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

R. Montironi | A. Ardizzoni | R. Golfieri | F. Massari | M. Santoni | A. Paccapelo | V. Mollica | A. Rizzo | F. Dall’Olio | S. Brocchi | L. Marcolin